NCT05927428View on ClinicalTrials.gov

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

November 30, 2025

Conditions
Neurotrophic Keratitis
Interventions
DRUG

BRM424 Ophthalmic Solution - Dose1

A topical drop of BRM424 ophthalmic solution.

DRUG

BRM424 Ophthalmic Solution - Dose2

A topical drop of BRM424 ophthalmic solution.

Trial Locations (1)

28451

RECRUITING

Wilmington Eye, Leland

Sponsors
All Listed Sponsors
lead

BRIM Biotechnology Inc.

INDUSTRY